Cosmo Sets Bold AI Vision at GI Industry’s Biggest Event of the Year
DUBLIN , IRELAND, 5TH MAY 2025 – Cosmo Pharmaceuticals is riding high on its ongoing innovations in AI and gastrointestinal drugs during this year’s Digestive Disease Week® (DDW) in San Diego from May 3 to May 6. As the premier event in the GI world, DDW sees a yearly attendance of over 13,000 gastroenterologists, scientists, and innovators in healthcare.
At the event, Cosmo’s Leadership is engaged in strategic meetings with Key Opinion Leaders (KOLs), innovators, and potential partners. These strategic discussions will cement relationships that are crucial to fast-tracking the company’s aspirations in AI-driven endoscopy and the discovery of new GI therapeutics.
“DDW is the epicentre of innovation in GI, and we are here to make meaningful progress,”
Said Giovanni Di Napoli, CEO of Cosmo. “We’re engaging with some of the brightest minds and most visionary partners to drive our AI and drug development efforts forward. The future of GI is being shaped now, and Cosmo is committed to being a catalyst in that transformation.”
As part of its engagement at DDW, Cosmo convened its AI Advisory Board, composed of top global experts, to help set strategic priorities and hasten progress in AI-based healthcare solutions.
Cosmo’s presence at DDW is another sign of its long-term commitment to merging science, technology, and execution to advance GI care. The company keeps investing in specific partnerships to better patient outcomes and further augment the set of tools available to clinicians around the globe.
CrowdStrike Unveils Agentic AI Innovations for Next-Gen SOC
Sonata Software Wins $73M AI-Led Digital Deal with US TMT Giant
